Sol-gel announces positive topline results from open-label, long-term safety study of epsolay® for treatment up to 52 weeks

Sol-gel announces positive topline results from open-label, long-term safety study of epsolay® for treatment up to 52 weeks.sol gel technologies - non-cutaneous adverse events were similar in frequency and type to those observed in preceding phase 3 trials.sol gel technologies ltd - no serious drug-related adverse events were reported in trial.
SLGL Ratings Summary
SLGL Quant Ranking